Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Califf

Showing results (81-90 of 567) with videos related to

Pageof 57
Sort By:
Clinical Pharmacology and Therapeutics|February 10, 2012
Impediments to clinical research in the United StatesJ M Kramer, P B Smith, R M Califf
Circulation|September 1, 1990
Is diagnostic certainty essential for the use of thrombolytic therapy during myocardial infarction in the 1990s?E M Ohman, K N Sigmon, R M Califf
Annals of Internal Medicine|April 1, 1997
Risk stratification after myocardial infarctionE D Peterson, L J Shaw, R M Califf
American Heart Journal|June 18, 1998
Outcomes and costs within a disease management program for advanced congestive heart failureK A Schulman, D B Mark, R M Califf
Controlled Clinical Trials|December 31, 1997
Developing systems for cost-effective auditing of clinical trialsR M Califf, S L Karnash, L H Woodlief
The New England Journal of Medicine|July 28, 1994
More on the GUSTO trialE J Topol, R M Califf, K L Lee
Circulation|February 1, 1996
Operator-specific outcomes. A call to professional responsibilityR M Califf, J G Jollis, E D Peterson
Circulation|December 1, 1986
Beyond randomized clinical trials: applying clinical experience in the treatment of patients with coronary artery diseaseR M Califf, D B Pryor, J C Greenfield
Journal of Cardiovascular Risk|April 1, 1997
Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trialsN E Jelesoff, M Feinglos, C B Granger, et al.
American Heart Journal|April 30, 1999
Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapyR M Califf, D Stump, E J Topol, et al.
Pageof 57

Showing results (81-90 of 567) with videos related to

Sort By:
Pageof 57
Clinical Pharmacology and Therapeutics|February 10, 2012
Impediments to clinical research in the United StatesJ M Kramer, P B Smith, R M Califf
Circulation|September 1, 1990
Is diagnostic certainty essential for the use of thrombolytic therapy during myocardial infarction in the 1990s?E M Ohman, K N Sigmon, R M Califf
Annals of Internal Medicine|April 1, 1997
Risk stratification after myocardial infarctionE D Peterson, L J Shaw, R M Califf
American Heart Journal|June 18, 1998
Outcomes and costs within a disease management program for advanced congestive heart failureK A Schulman, D B Mark, R M Califf
Controlled Clinical Trials|December 31, 1997
Developing systems for cost-effective auditing of clinical trialsR M Califf, S L Karnash, L H Woodlief
The New England Journal of Medicine|July 28, 1994
More on the GUSTO trialE J Topol, R M Califf, K L Lee
Circulation|February 1, 1996
Operator-specific outcomes. A call to professional responsibilityR M Califf, J G Jollis, E D Peterson
Circulation|December 1, 1986
Beyond randomized clinical trials: applying clinical experience in the treatment of patients with coronary artery diseaseR M Califf, D B Pryor, J C Greenfield
Journal of Cardiovascular Risk|April 1, 1997
Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trialsN E Jelesoff, M Feinglos, C B Granger, et al.
American Heart Journal|April 30, 1999
Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapyR M Califf, D Stump, E J Topol, et al.
Pageof 57